This company has been marked as potentially delisted and may not be actively trading. HealthCor Catalio Acquisition (HCAQ) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock HCAQ vs. IKNA, YI, CTSO, AKYA, VTGN, ADAP, FORA, BMEA, CNTB, and CLSDShould you be buying HealthCor Catalio Acquisition stock or one of its competitors? The main competitors of HealthCor Catalio Acquisition include Ikena Oncology (IKNA), 111 (YI), Cytosorbents (CTSO), Akoya Biosciences (AKYA), VistaGen Therapeutics (VTGN), Adaptimmune Therapeutics (ADAP), Forian (FORA), Biomea Fusion (BMEA), Connect Biopharma (CNTB), and Clearside Biomedical (CLSD). These companies are all part of the "medical" sector. HealthCor Catalio Acquisition vs. Its Competitors Ikena Oncology 111 Cytosorbents Akoya Biosciences VistaGen Therapeutics Adaptimmune Therapeutics Forian Biomea Fusion Connect Biopharma Clearside Biomedical HealthCor Catalio Acquisition (NASDAQ:HCAQ) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk. Which has better valuation and earnings, HCAQ or IKNA? HealthCor Catalio Acquisition has higher earnings, but lower revenue than Ikena Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHealthCor Catalio AcquisitionN/AN/AN/AN/AN/AIkena Oncology$9.16M7.27-$49.23M-$0.86-1.60 Does the media favor HCAQ or IKNA? In the previous week, Ikena Oncology had 5 more articles in the media than HealthCor Catalio Acquisition. MarketBeat recorded 5 mentions for Ikena Oncology and 0 mentions for HealthCor Catalio Acquisition. Ikena Oncology's average media sentiment score of 0.95 beat HealthCor Catalio Acquisition's score of 0.00 indicating that Ikena Oncology is being referred to more favorably in the news media. Company Overall Sentiment HealthCor Catalio Acquisition Neutral Ikena Oncology Positive Do institutionals and insiders hold more shares of HCAQ or IKNA? 84.2% of HealthCor Catalio Acquisition shares are held by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are held by institutional investors. 5.9% of Ikena Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is HCAQ or IKNA more profitable? HealthCor Catalio Acquisition's return on equity of 0.00% beat Ikena Oncology's return on equity.Company Net Margins Return on Equity Return on Assets HealthCor Catalio AcquisitionN/A N/A N/A Ikena Oncology N/A -30.59%-27.55% Do analysts prefer HCAQ or IKNA? Ikena Oncology has a consensus price target of $3.00, suggesting a potential upside of 117.39%. Given Ikena Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Ikena Oncology is more favorable than HealthCor Catalio Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HealthCor Catalio Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryIkena Oncology beats HealthCor Catalio Acquisition on 7 of the 10 factors compared between the two stocks. Get HealthCor Catalio Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for HCAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HCAQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HCAQ vs. The Competition Export to ExcelMetricHealthCor Catalio AcquisitionX IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.39M$11.41B$5.56B$9.10BDividend YieldN/A1.84%5.06%4.02%P/E RatioN/A18.3328.2620.26Price / SalesN/A7.60427.10161.28Price / CashN/A11.9037.1257.67Price / BookN/A2.028.045.49Net IncomeN/A$344.53M$3.19B$250.45M HealthCor Catalio Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HCAQHealthCor Catalio AcquisitionN/A$0.77-1.9%N/A-26.1%$16.39MN/A0.002IKNAIkena Oncology2.7867 of 5 stars$1.37+1.5%$3.00+119.0%-19.3%$65.15M$9.16M-1.5970News CoverageYI1110.1816 of 5 stars$7.27-2.9%N/A-35.1%$64.73M$1.97B-11.361,238News CoverageCTSOCytosorbents1.5119 of 5 stars$1.05+1.9%$5.50+423.8%-1.9%$64.49M$35.60M-3.75220Gap UpAKYAAkoya Biosciences2.0171 of 5 stars$1.29-5.1%$2.51+94.3%N/A$64.44M$81.67M-1.3390Gap UpVTGNVistaGen Therapeutics0.934 of 5 stars$2.46+11.3%N/A-38.0%$64.44M$490K-1.4840High Trading VolumeADAPAdaptimmune Therapeutics1.9861 of 5 stars$0.25+4.9%$1.35+434.3%-79.0%$63.90M$178.03M-0.94490Gap DownFORAForian2.5773 of 5 stars$2.04-0.5%$5.00+145.1%-20.4%$63.65M$22.33M-22.67140Gap DownBMEABiomea Fusion3.3914 of 5 stars$1.86+10.1%$21.40+1,050.5%-62.2%$63.50MN/A-0.5250Positive NewsCNTBConnect Biopharma3.137 of 5 stars$1.13-0.4%$7.00+516.8%+21.6%$63.34M$26.03M0.00110News CoverageGap UpCLSDClearside Biomedical2.0192 of 5 stars$0.83+2.2%$4.75+470.4%-29.2%$63.33M$1.66M-2.0330Positive News Related Companies and Tools Related Companies IKNA Competitors YI Competitors CTSO Competitors AKYA Competitors VTGN Competitors ADAP Competitors FORA Competitors BMEA Competitors CNTB Competitors CLSD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HCAQ) was last updated on 7/13/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HealthCor Catalio Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share HealthCor Catalio Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
